Last updated on August 2018

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease


Brief description of study

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) [ADAS-Cog 13], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) [ADCS-ADL-MCI].

Clinical Study Identifier: NCT02477800

Contact Investigators or Research Sites near you

Start Over

Aducanumab Global Clinical Trial Center

Seoul National University Bundang Hospital
Seongnam-si, Korea, Republic of

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.